Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price shot up 1.7% during mid-day trading on Thursday . The stock traded as high as $54.14 and last traded at $53.74. 366,596 shares changed hands during trading, an increase of 94% from the average session volume of 189,291 shares. The stock had previously closed at $52.83.
Gemini Therapeutics Stock Performance
The stock’s 50 day simple moving average is $55.40 and its 200 day simple moving average is $55.98. The firm has a market cap of $2.26 billion, a PE ratio of -52.24 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- How to Evaluate a Stock Before Buying
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Investing In Preferred Stock vs. Common Stock
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
